34 results on '"Huguet, F."'
Search Results
2. P477: PHENOTYPICALLY‐DEFINED STAGES OF LEUKEMIA ARREST PREDICT MAIN DRIVER MUTATIONS SUBGROUPS, AND OUTCOME IN ACUTE MYELOID LEUKEMIA.
- Author
-
Vergez, F., Largeaud, L., Bertoli, S., Nicolau‐Travers, M.‐L., Rieu, J.‐B., Vergnolle, I., Saland, E., Sarry, A., Tavitian, S., Huguet, F., Picard, M., Vial, J.‐P., Lechevalier, N., Bidet, A., Dumas, P.‐Y., Pigneux, A., Luquet, I., Mansat‐De Mas, V., Delabesse, E., and Carroll, M.
- Published
- 2022
- Full Text
- View/download PDF
3. A new method to prepare no-carrier-added iodinated spirodecanone derivatives:1 application to dopaminergic and serotoninergic ligands.
- Author
-
Frangin, Y., Callet, M., Chalon, S., Huguet, F., Foulon, C., Desplanches, G., Baulieu, J- L., Besnard, J-C., and Guilloteau, D.
- Published
- 1990
- Full Text
- View/download PDF
4. Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients.
- Author
-
Robert, J., Rigal-Huguet, F., and Hurteloup, P.
- Published
- 1992
- Full Text
- View/download PDF
5. Central 5HT1A-receptor binding in normotensive and spontaneously hypertensive rats.
- Author
-
Huguet, F. and Brisac, AM
- Published
- 1991
- Full Text
- View/download PDF
6. CENTRAL CARDIOVASCULAR EFFECTS OF DIHYDROPYRIDINES IN SPONTANEOUSLY HYPERTENSIVE RATS.
- Author
-
LAURENT, S., BRISAC, A.M., CHAMPEROUX, P., LACOLLEY, P., HUGUET, F., LEGRAND, M., LUCET, B., TSOUCARIS, D., BRIAND, V., and SCHMITT, H.
- Published
- 1989
- Full Text
- View/download PDF
7. CENTRAL NEUROCHEMICAL EFFECTS OF DIHYDROPYRIDINE CALCIUM ANTAGONISTS.
- Author
-
HUGUET, F.
- Published
- 1989
- Full Text
- View/download PDF
8. Treatment of acute myeloid leukemia in elderly patients with oral idarubicin as a single agent.
- Author
-
Harousseau, J. L., Rigal-Huguet, F., Hurteloup, P., Guy, H., Milpied, N., and Pris, J.
- Published
- 1989
- Full Text
- View/download PDF
9. Cytodiagnosis of Rhabdomyosarcoma In Serous Effusions: Cytological and Immunocytochemical Findings of Two Unusual Clinical Cases.
- Author
-
DASTE, G., VOIGT, J.-J., RUBIE, H., ROBERT, A., RIGAL-HUGUET, F., CAUNES, N., and SOLEILHAVOUP, J.-P.
- Published
- 1993
- Full Text
- View/download PDF
10. INTENSIVE INDUCTION CHEMOTHERAPY IN ELDERLY PATIENTS.
- Author
-
Reiffers, J., Huguet, F., Stoppa, A. M., Michallet, M., Hurteloup, P., Liu Yin, John A., and Hutchinson, R. M.
- Published
- 1992
- Full Text
- View/download PDF
11. ChemInform Abstract: Synthesis and Pharmacological Activities of Some Substituted Thienopyrimidin-4-ones.
- Author
-
PERRISSIN, M., FAVRE, M., LUU DUC CUONG, LUU DUC CUONG, HUGUET, F., GAULTIER, C., and NARCISSE, G.
- Published
- 1989
- Full Text
- View/download PDF
12. ChemInform Abstract: Fluorinated Phenylethylamines, Synthesis and Neurobiochemical Studies in the Rat.
- Author
-
CHARLON, C., LUU-DUC, C., HUGUET, F., GERARD, P., and NARCISSE, G.
- Published
- 1987
- Full Text
- View/download PDF
13. ChemInform Abstract: Synthesis, Binding Affinity and Antioxidant Activity of New 1,4- Dihydropyridines.
- Author
-
LEHUEDE, J., HUGUET, F., FAUCONNEAU, B., PIRIOU, A., and VIERFOND, J. M.
- Published
- 1996
- Full Text
- View/download PDF
14. Management of intrahepatic and perihilar cholangiocarcinomas: Guidelines of the French Association for the Study of the Liver (AFEF).
- Author
-
Neuzillet C, Decraecker M, Larrue H, Ntanda-Nwandji LC, Barbier L, Barge S, Belle A, Chagneau C, Edeline J, Guettier C, Huguet F, Jacques J, Le Bail B, Leblanc S, Lewin M, Malka D, Ronot M, Vendrely V, Vibert É, Bureau C, Bourliere M, Ganne-Carrie N, and Blanc JF
- Abstract
Intrahepatic cholangiocarcinoma (iCCA) is the second most common malignant primary liver cancer. iCCA may develop on an underlying chronic liver disease and its incidence is growing in relation with the epidemics of obesity and metabolic diseases. In contrast, perihilar cholangiocarcinoma (pCCA) may follow a history of chronic inflammatory diseases of the biliary tract. The initial management of CCAs is often complex and requires multidisciplinary expertise. The French Association for the Study of the Liver wished to organize guidelines in order to summarize the best evidence available about several key points in iCCA and pCCA. These guidelines have been elaborated based on the level of evidence available in the literature and each recommendation has been analysed, discussed and voted by the panel of experts. They describe the epidemiology of CCA as well as how patients with iCCA or pCCA should be managed from diagnosis to treatment. The most recent developments of personalized medicine and use of targeted therapies are also highlighted., (© 2024 The Authors. Liver International published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
15. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia.
- Author
-
Jabbour E, Zugmaier G, Agrawal V, Martínez-Sánchez P, Rifón Roca JJ, Cassaday RD, Böll B, Rijneveld A, Abdul-Hay M, Huguet F, Cluzeau T, Díaz MT, Vucinic V, González-Campos J, Rambaldi A, Schwartz S, Berthon C, Hernández-Rivas JM, Gordon PR, Brüggemann M, Hamidi A, Chen Y, Wong HL, Panwar B, Katlinskaya Y, Markovic A, and Kantarjian H
- Subjects
- Adult, Humans, Remission Induction, Pathologic Complete Response, Acute Disease, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Antibodies, Bispecific adverse effects, Lymphoma, B-Cell drug therapy, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Antineoplastic Agents adverse effects
- Abstract
Blinatumomab is a BiTE® (bispecific T-cell engager) molecule that redirects CD3
+ T-cells to engage and lyse CD19+ target cells. Here we demonstrate that subcutaneous (SC) blinatumomab can provide high efficacy and greater convenience of administration. In the expansion phase of a multi-institutional phase 1b trial (ClinicalTrials.gov, NCT04521231), heavily pretreated adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) received SC blinatumomab at two doses: (1) 250 μg once daily (QD) for week 1 and 500 μg three times weekly (TIW) thereafter (250 μg/500 μg) or (2) 500 μg QD for week 1 and 1000 μg TIW thereafter (500 μg/1000 μg). The primary endpoint was complete remission/complete remission with partial hematologic recovery (CR/CRh) within two cycles. At the data cutoff of September 15, 2023, 29 patients were treated: 14 at the 250 μg/500 μg dose and 13 at 500 μg/1000 μg dose. Data from two ineligible patients were excluded. At the end of two cycles, 12 of 14 patients (85.7%) from the 250 μg/500 μg dose achieved CR/CRh of which nine patients (75.0%) were negative for measurable residual disease (MRD; <10-4 leukemic blasts). At the 500 μg/1000 μg dose, 12 of 13 patients (92.3%) achieved CR/CRh; all 12 patients (100.0%) were MRD-negative. No treatment-related grade 4 cytokine release syndrome (CRS) or neurologic events (NEs) were reported. SC injections were well tolerated and all treatment-related grade 3 CRS and NEs responded to standard-of-care management, interruption, or discontinuation. Treatment with SC blinatumomab resulted in high efficacy, with high MRD-negativity rates and acceptable safety profile in heavily pretreated adults with R/R B-ALL., (© 2024 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.)- Published
- 2024
- Full Text
- View/download PDF
16. Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in chronic phase chronic myelogenous leukaemia patients.
- Author
-
Alcazer V, Morisset S, Rea D, Legros L, Dulucq S, Hayette S, Cayuela JM, Huguet F, Mahon FX, Etienne G, and Nicolini FE
- Subjects
- Humans, Protein Kinase Inhibitors therapeutic use, Imatinib Mesylate, Tyrosine Kinase Inhibitors, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy
- Published
- 2024
- Full Text
- View/download PDF
17. Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment-free remission period after imatinib discontinuation: Results of the French Nilo post-STIM study.
- Author
-
Dulucq S, Rigal-Huguet F, Nicolini FE, Cony-Makhoul P, Escoffre-Barbe M, Gardembas M, Legros L, Rousselot P, Liu J, Rea D, De Mas V, Hayette S, Raynaud S, Lacoste-Roussillon C, Robbesyn F, Klein E, Morisset S, Mahon FX, and Etienne G
- Subjects
- Humans, Imatinib Mesylate adverse effects, Pyrimidines adverse effects, Treatment Outcome, Protein Kinase Inhibitors adverse effects, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy
- Abstract
Molecular recurrence (MRec) occurs in about half of all patients with chronic myeloid leukaemia (CML) who discontinue tyrosine kinase inhibitors (TKI) in sustained deep molecular response. A second TKI discontinuation has been attempted in some patients who regain the discontinuation criteria after resuming treatment. Nilotinib treatment affords faster and deeper molecular responses than imatinib as first-line therapy. We prospectively evaluated the efficacy and safety of nilotinib (300 mg twice daily) in chronic-phase CML patients who experienced MRec, after imatinib discontinuation and analysed the probability of TFR after a new attempt in patients treated for 2 years with sustained MR
4.5 for at least 1 year. A total of 31 patients were included in the study between 2013 and 2018. Seven (23%) patients experienced serious adverse events after a median of 2 months of nilotinib treatment leading to discontinuation of treatment. One patient was excluded from the study for convenience. Among the 23 patients treated for 2 years with nilotinib, 22 maintained their molecular response for at least 1 year (median: 22 months) and stopped nilotinib. The TFR rates at 24 and 48 months after nilotinib discontinuation were 59.1% (95% confidence interval [CI]: 41.7%-83.7%) and 42.1% (95% CI: 25%-71%) respectively (NCT #01774630)., (© 2023 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.)- Published
- 2023
- Full Text
- View/download PDF
18. Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA-PegIFN study).
- Author
-
Roy L, Chomel JC, Guilhot J, Guerci-Bresler A, Escoffre-Barbe M, Giraudier S, Charbonnier A, Dubruille V, Huguet F, Johnson-Ansah H, Lenain P, Ame S, Etienne G, Nicolini FE, Rea D, Cony-Makhoul P, Courby S, Ianotto JC, Legros L, Machet A, Coiteux V, Hermet E, Cayssials E, Bouchet S, Mahon FX, Rousselot P, and Guilhot F
- Subjects
- Humans, Aged, Dasatinib adverse effects, Polyethylene Glycols adverse effects, Treatment Outcome, Interferon-alpha adverse effects, Leukemia, Myeloid, Chronic-Phase drug therapy
- Abstract
Superior rates of deep molecular response (DMR) have been reported with the combination of tyrosine kinase inhibitors and pegylated-interferon-alpha (Peg-IFN) in patients with newly diagnosed chronic phase-chronic myeloid leukaemia (CP-CML). In this setting, this study investigated the efficacy and safety of dasatinib combined to Peg-IFN-α2b (Dasa-PegIFN, NCT01872442). A total of 79 patients (age ≤65 years) started dasatinib; 61 were eligible for Peg-IFNα-2b add-on therapy at month 3 for a maximum 21-months duration. Dasatinib was continued thereafter. The primary endpoint was the cumulative rate of molecular response 4.5 log (MR
4.5 ) by 12 months. The results are reported for the 5-year duration of the study. Grade 3 neutropenia was frequent with the combination but did not induce severe infection (one of grade 3). Other adverse events were generally low grade (4% of grade 3-4) and expected. Seventy-nine per cent and 61% of patients continued the Peg-IFN until months 12 and 24, respectively. Overall, at these time points, MR4.5 rates were 25% and 38%, respectively. Thereafter, 32% and 46% of patients achieved a sustained (≥2 years) MR4.5 or MR4 , respectively. This work established the feasibility and high rates of achievement of early and sustained DMR (a prerequisite for treatment-free-remission) with dasatinib and Peg-IFNα-2b combination as initial therapy., (© 2022 British Society for Haematology and John Wiley & Sons Ltd.)- Published
- 2023
- Full Text
- View/download PDF
19. Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients.
- Author
-
Rousselot P, Mollica L, Guilhot J, Guerci A, Nicolini FE, Etienne G, Legros L, Charbonnier A, Coiteux V, Dartigeas C, Escoffre-Barbe M, Roy L, Cony-Makhoul P, Dubruille V, Gardembas M, Huguet F, Réa D, Cayssials E, Guilhot F, Bergeron A, Molimard M, Mahon FX, Cayuela JM, Busque L, and Bouchet S
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Agents administration & dosage, Antineoplastic Agents adverse effects, Dasatinib administration & dosage, Dasatinib adverse effects, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Pleural Effusion prevention & control, Prospective Studies, Protein Kinase Inhibitors administration & dosage, Protein Kinase Inhibitors adverse effects, Treatment Outcome, Young Adult, Antineoplastic Agents therapeutic use, Dasatinib therapeutic use, Drug Monitoring, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Pleural Effusion chemically induced, Protein Kinase Inhibitors therapeutic use
- Abstract
Dasatinib is a second-generation BCR-ABL1 tyrosine kinase inhibitor approved for patients with chronic myeloid leukaemia (CML). Dasatinib 100 mg per day is associated with an increased risk of pleural effusion (PlEff). We randomly evaluated whether therapeutic drug monitoring (TDM) may reduce dasatinib-associated significant adverse events (AEs) by 12 months (primary endpoint). Eligible patients started dasatinib at 100 mg per day followed by dasatinib (C)min assessment. Patients considered overdosed [(C)min ≥ 3 nmol/l) were randomised between a dose-reduction strategy (TDM arm) and standard of care (control arm). Out of 287 evaluable patients, 80 patients were randomised. The primary endpoint was not met due to early haematological AEs occurring before effective dose reduction. However, a major reduction in the cumulative incidence of PlEff was observed in the TDM arm compared to the control arm (4% vs. 15%; 11% vs. 35% and 12% vs. 39% at one, two and three years, respectively (P = 0·0094)). Molecular responses were superimposable in all arms. Dasatinib TDM during treatment initiation was feasible and resulted in a significant reduction of the incidence of PlEff in the long run, without impairing molecular responses. (NCT01916785; https://clinicaltrials.gov)., (© 2021 British Society for Haematology and John Wiley & Sons Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
20. Nilotinib efficacy, safety, adherence and impact on quality of life in newly diagnosed patients with chronic myeloid leukaemia in chronic phase: a prospective observational study in daily clinical practice.
- Author
-
Huguet F, Cayuela JM, Cambier N, Carpentier N, Tindel M, Violet I, Zunic P, Lascaux A, and Etienne G
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Agents adverse effects, Asthenia chemically induced, Biomarkers, Tumor genetics, Drug Eruptions etiology, Female, Follow-Up Studies, Fusion Proteins, bcr-abl genetics, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics, Male, Medication Adherence statistics & numerical data, Middle Aged, Prospective Studies, Protein-Tyrosine Kinases antagonists & inhibitors, Pruritus chemically induced, Psychometrics, Pyrimidines adverse effects, Treatment Outcome, Young Adult, Antineoplastic Agents therapeutic use, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Pyrimidines therapeutic use, Quality of Life
- Abstract
This observational, prospective study assessed, in a daily clinical practice, the molecular response, safety, quality of life (QoL) and treatment adherence in 183 patients with chronic myeloid leukaemia in chronic phase (CML-CP), receiving nilotinib as first-line treatment. Premature study termination before 24 months of follow-up occurred in 61 patients (33·3%), and was essentially due to nilotinib treatment discontinuation (n = 53; 29%), motivated by treatment intolerance (n = 29; 15·8%) and inefficacy (n = 19; 10·4%). After 24 months of treatment, 112/122 patients (91·8%) had a molecular assessment, 95·5% of whom achieved a major molecular response (MMR), 32·1% achieved uMR
4 , defined as an undetectable molecular disease with 4-log molecular response sensitivity (≥10 000 ABL1 transcripts). The Morisky Green Levine Medication Adherence Scale was completed by 94/122 patients (77·0%), and 89·4% of these patients obtained a satisfactory level of treatment adherence, defined as a score ≥3. Patients' QoL was good at baseline and stable during the follow-up period. The two most common nilotinib-related adverse events (AEs) were pruritus (14·8%) and asthenia (13·7%). Seven patients (3·8%) experienced at least one cardiovascular ischaemic AE. This French nationwide cohort study provides relevant information in daily clinical practice indicating that nilotinib is a valuable first-line treatment option for CML-CP patients., (© 2019 British Society for Haematology and John Wiley & Sons Ltd.)- Published
- 2019
- Full Text
- View/download PDF
21. Bendamustine for relapsed blastic plasmacytoid dendritic cell leukaemia.
- Author
-
Bétrian S, Guenounou S, Luquet I, Demur C, Huynh A, Ysebaert L, Recher C, and Huguet F
- Subjects
- Aged, Blast Crisis, Hematologic Neoplasms pathology, Humans, Male, Middle Aged, Recurrence, Antineoplastic Agents, Alkylating therapeutic use, Bendamustine Hydrochloride therapeutic use, Dendritic Cells pathology, Hematologic Neoplasms drug therapy
- Abstract
Optimal treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare entity of dismal prognosis previously described as CD4+/CD56+ hematodermic malignancies, is not defined. We report five cases of relapsed BPDCN treated with bendamustine hydrochloride, a well-tolerated bifunctional drug acting as an alkylating and antimetabolite agent. All patients were above the age of 50 years and in advanced disease (early first relapse in two, subsequent relapse in three; multi-organ involvement in four; previous intensive chemotherapy in five; and stem cell transplantation in four). Four patients were evaluable for response. Two failed therapy, one died from tumor lysis syndrome after rapid blast clearance from blood, and one reached and maintained complete remission for 7 months. Bendamustine should be further evaluated in BPDCN. Copyright © 2015 John Wiley & Sons, Ltd., (Copyright © 2015 John Wiley & Sons, Ltd.)
- Published
- 2017
- Full Text
- View/download PDF
22. Impact of ELN recommendations in the management of first-line treated chronic myeloid leukaemia patients: a French cross-sectional study.
- Author
-
Etienne G, Huguet F, Guerci-Bresler A, Nicolini FE, Maloisel F, Coiteux V, Dauriac C, Carpentier N, Bourdeix I, Tulliez M, and Cony-Makhoul P
- Subjects
- Aged, Cross-Sectional Studies, Drug Monitoring, Female, France epidemiology, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Leukemia, Myelogenous, Chronic, BCR-ABL Positive epidemiology, Leukemia, Myeloid, Chronic-Phase epidemiology, Male, Middle Aged, Practice Guidelines as Topic, Protein Kinase Inhibitors therapeutic use, Protein-Tyrosine Kinases antagonists & inhibitors, Remission Induction methods, Time Factors, Leukemia, Myeloid, Chronic-Phase drug therapy
- Abstract
The availability of tyrosine kinase inhibitors has extended therapeutic options for chronic myeloid leukaemia (CML) patients. Monitoring recommendations and clinical response goals have recently been updated. The objective of this study was to describe the profile of CML patients in chronic phase currently receiving first-line therapy, including treatment, monitoring and response kinetics. A multicentre, cross-sectional, epidemiological survey in unselected chronic phase CML patients in France attending consultations during a one-month period was performed. 438 of 697 (62·8%) reported patients were currently receiving first-line treatment and were analysed. Imatinib was the most frequently received treatment (72·4% of patients). Retrospective cytogenetic and molecular assessments at 3, 6, 12 or 18 months were available in 88·4% of patients. At the 12-month assessment, 32·2% were not in major molecular response (MMR). At last assessment, among 355 patients with duration of treatment ≥ 12 months, 91·5% had achieved MMR and 66·5% were in deep molecular response. This study, performed in everyday practice population of CML patients, suggests that monitoring of molecular responses in real-life practice is aligned with European LeukaemiaNet recommendations. The majority of patients still receiving first-line treatment are in optimal response, with a few being classified as in the warning area or responding to failure., (© 2016 John Wiley & Sons Ltd.)
- Published
- 2016
- Full Text
- View/download PDF
23. Impact of obesity in favorable-risk AML patients receiving intensive chemotherapy.
- Author
-
Tavitian S, Denis A, Vergez F, Berard E, Sarry A, Huynh A, Delabesse E, Luquet I, Huguet F, Récher C, and Bertoli S
- Subjects
- Aged, Body Mass Index, Body Surface Area, Disease-Free Survival, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Induction Chemotherapy, Leukemia, Myeloid, Acute complications, Leukemia, Myeloid, Acute mortality, Male, Middle Aged, Multivariate Analysis, Obesity mortality, Retrospective Studies, Risk, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Leukemia, Myeloid, Acute drug therapy, Obesity complications
- Abstract
We assessed the influence of obesity on the characteristics and prognosis of acute myeloid leukemia (AML). Indeed, safety of intensive chemotherapy and outcome of obese AML patients in a real-life setting are poorly described, and chemotherapy dosing remains challenging. We included 619 consecutive genetically-defined cases of AML treated with intensive chemotherapy between 2004 and 2012. In this cohort, 93 patients (15%) were classified in the obese category according to WHO classification; 59% of them received capped doses of chemotherapy because of a body surface area above 2 m(2) . Obese patients were older and presented more often with cardiovascular comorbidities. Although obese patients had more frequently de novo AML, main characteristics of AML including white blood cell count, karyotype and mutations were well-balanced between obese and non-obese patients. After induction chemotherapy, early death and complete remission rates were similar. Overall (OS), event-free (EFS) and disease-free (DFS) survival were not significantly different compared to non-obese patients. However, in the European LeukemiaNet (ELN) favorable subgroup, obese patients had lower median OS, EFS and DFS than non-obese patients (18.4, 16.8 and 17.2 vs. 43.6, 31.8 and 29.7 months, respectively) and obesity showed a significant impact on OS (OR 2.54; P = 0.02) in multivariate models. Although we did not find any significant impact of obesity on outcome in the whole series, this study suggests that special efforts for chemotherapy dose optimization are needed in the ELN favorable subgroup since dose capping may be deleterious., (© 2015 Wiley Periodicals, Inc.)
- Published
- 2016
- Full Text
- View/download PDF
24. Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l-asparaginase: The GRAALL experience.
- Author
-
Couturier MA, Huguet F, Chevallier P, Suarez F, Thomas X, Escoffre-Barbe M, Cacheux V, Pignon JM, Bonmati C, Sanhes L, Bories P, Daguindau E, Dorvaux V, Reman O, Frayfer J, Orvain C, Lhéritier V, Ifrah N, Dombret H, Hunault-Berger M, and Tanguy-Schmidt A
- Subjects
- Adolescent, Adult, Antithrombins blood, Cerebral Veins drug effects, Cerebral Veins pathology, Drug Administration Schedule, Female, Fibrinolytic Agents therapeutic use, Heparin therapeutic use, Humans, Induction Chemotherapy, Male, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma complications, Precursor Cell Lymphoblastic Leukemia-Lymphoma mortality, Precursor Cell Lymphoblastic Leukemia-Lymphoma pathology, Retrospective Studies, Risk Factors, Survival Analysis, Time Factors, Venous Thrombosis etiology, Venous Thrombosis mortality, Venous Thrombosis pathology, Antineoplastic Agents therapeutic use, Asparaginase therapeutic use, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Venous Thrombosis drug therapy
- Abstract
Central nervous system (CNS) thrombotic events are a well-known complication of acute lymphoblastic leukemia (ALL) induction therapy, especially with treatments including l-asparaginase (l-ASP). Data on risk factors and clinical evolution is still lacking in adult patients. We report on the clinical evolution of 22 CNS venous thrombosis cases occurring in 708 adults treated for ALL or lymphoblastic lymphoma (LL) with the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL)-induction protocol, which included eight L-ASP (6,000 IU/m(2) ) infusions. The prevalence of CNS thrombosis was 3.1%. CNS thrombosis occurred after a median of 18 days (range: 11-31) when patients had received a median of three l-ASP injections (range: 2-7). Patients with CNS thrombosis exhibited a median antithrombin (AT) nadir of 47.5% (range: 36-67%) at Day 17 (range: D3-D28), and 95% of them exhibited AT levels lower than 60%. There were no evident increase in hereditary thrombotic risk factors prevalence, and thrombosis occurred despite heparin prophylaxis which was performed in 90% of patients. Acquired AT deficiency was frequently detected in patients with l-ASP-based therapy, and patients with CNS thrombosis received AT prophylaxis (45%) less frequently than patients without CNS thrombosis (83%), P = 0.0002). CNS thrombosis was lethal in 5% of patients, while 20% had persistent sequelae. One patient received all planned l-ASP infusions without recurrence of CNS thrombotic whereas l-ASP injections were discontinued in 20 patients during the management of thrombosis without a significant impact on overall survival (P = 0.4)., (© 2015 Wiley Periodicals, Inc.)
- Published
- 2015
- Full Text
- View/download PDF
25. A Phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL-SA2-2008 study.
- Author
-
Hunault-Berger M, Leguay T, Huguet F, Leprêtre S, Deconinck E, Ojeda-Uribe M, Bonmati C, Escoffre-Barbe M, Bories P, Himberlin C, Chevallier P, Rousselot P, Reman O, Boulland ML, Lissandre S, Turlure P, Bouscary D, Sanhes L, Legrand O, Lafage-Pochitaloff M, Béné MC, Liens D, Godfrin Y, Ifrah N, and Dombret H
- Subjects
- Aged, Anti-Bacterial Agents therapeutic use, Antifungal Agents therapeutic use, Asparagine metabolism, Drug Carriers, Drug Compounding, Erythrocytes chemistry, Erythrocytes cytology, Female, Gram-Negative Bacterial Infections complications, Gram-Negative Bacterial Infections mortality, Gram-Negative Bacterial Infections pathology, Gram-Positive Bacterial Infections complications, Gram-Positive Bacterial Infections mortality, Gram-Positive Bacterial Infections pathology, Humans, Male, Middle Aged, Mycoses complications, Mycoses mortality, Mycoses pathology, Philadelphia Chromosome, Precursor Cell Lymphoblastic Leukemia-Lymphoma complications, Precursor Cell Lymphoblastic Leukemia-Lymphoma mortality, Precursor Cell Lymphoblastic Leukemia-Lymphoma pathology, Remission Induction, Survival Analysis, Antineoplastic Combined Chemotherapy Protocols, Asparaginase therapeutic use, Gram-Negative Bacterial Infections drug therapy, Gram-Positive Bacterial Infections drug therapy, Mycoses drug therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy
- Abstract
Purpose: The GRASPALL/GRAALL-SA2-2008 Phase II trial evaluated the safety and efficacy of L-asparaginase encapsulated within erythrocytes (GRASPA®) in patients ≥ 55 years with Philadelphia chromosome-negative acute lymphoblastic leukemia., Findings: Thirty patients received escalating doses of GRASPA® on Day 3 and 6 of induction Phases 1 and 2. The primary efficacy endpoint was asparagine depletion < 2 µmol/L for at least 7 days. This was reached in 85 and 71% of patients with 100 and 150 IU/kg respectively but not with 50 IU/kg. Grade 3/4 infection, hypertransaminasemia, hyperbilirubinemia and deep vein thrombosis occurred in 77, 20, 7, and 7% of patients, respectively. No allergic reaction or clinical pancreatitis was observed despite 17% of Grade 3/4 lipase elevation. Anti-asparaginase antibodies were detected in 50% of patients and related to a reduction in the duration of asparagine depletion during induction Phase 2 without decrease of encapsulated L-asparaginase activity. Complete remission rate was 70%. With a median follow-up of 42 months, median overall survival was 15.8 and 9.7 months, in the 100 and 150 IU/kg cohorts respectively., Conclusions: The addition of GRASPA®, especially at the 100 IU/kg dose level, is feasible in elderly patients without excessive toxicity and associated with durable asparagine depletion. (clinicaltrials.gov identifier NCT01523782)., (© 2015 Wiley Periodicals, Inc.)
- Published
- 2015
- Full Text
- View/download PDF
26. Comparison of 60 or 90 mg/m(2) of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics.
- Author
-
Devillier R, Bertoli S, Prébet T, Huguet F, Etienne A, Charbonnier A, Rey J, Delabesse E, D'Incan E, Huynh A, Blaise D, Récher C, and Vey N
- Subjects
- Adolescent, Adult, Clinical Trials as Topic, Cytogenetic Analysis, Drug Administration Schedule, Female, Genotype, Humans, Leukemia, Myeloid, Acute mortality, Leukemia, Myeloid, Acute pathology, Male, Middle Aged, Remission Induction, Retrospective Studies, Survival Analysis, Antibiotics, Antineoplastic therapeutic use, Daunorubicin therapeutic use, Leukemia, Myeloid, Acute drug therapy, Leukemia, Myeloid, Acute genetics
- Published
- 2015
- Full Text
- View/download PDF
27. Intensive chemotherapy, azacitidine, or supportive care in older acute myeloid leukemia patients: an analysis from a regional healthcare network.
- Author
-
Bories P, Bertoli S, Bérard E, Laurent J, Duchayne E, Sarry A, Delabesse E, Beyne-Rauzy O, Huguet F, and Récher C
- Subjects
- Aged, Aged, 80 and over, Female, France, Humans, L-Lactate Dehydrogenase, Leukemia, Myeloid, Acute diagnosis, Leukemia, Myeloid, Acute mortality, Lymphocyte Count, Male, Middle Aged, Multivariate Analysis, Prognosis, Prospective Studies, Regional Medical Programs, Survival Analysis, Antimetabolites, Antineoplastic therapeutic use, Antineoplastic Combined Chemotherapy Protocols, Azacitidine therapeutic use, Leukemia, Myeloid, Acute pathology, Leukemia, Myeloid, Acute therapy, Palliative Care
- Abstract
We assessed in a French regional healthcare network the distribution of treatments, prognostic factors, and outcome of 334 newly diagnosed acute myeloid leukemia patients aged 60 years or older over a 4-year period of time (2007-2010). Patients were selected in daily practice for intensive chemotherapy (n = 115), azacitidine (n = 95), or best supportive care (n = 124). In these three groups, median overall survival was 18.9, 11.3, and 1.8 months, respectively. In the azacitidine group, multivariate analysis showed that overall survival was negatively impacted by higher age (P = 0.010 for one unit increase), unfavorable cytogenetics (P = 0.001), lymphocyte count <0.5 G/L (P = 0.015), and higher lactate dehydrogenase level (P = 0.005 for one unit increase). We compared the survival of patients treated by azacitidine versus intensive chemotherapy and best supportive care using time-dependent analysis and propensity score matching. Patients treated by intensive chemotherapy had a better overall survival compared with those treated by azacitidine from 6 months after diagnosis, whereas patients treated by azacitidine had a better overall survival compared with those treated by best supportive care from 1 day after diagnosis. This study of "real life" practice shows that there is a room for low intensive therapies such as azacitidine in selected elderly acute myeloid leukemia patients., (© 2014 Wiley Periodicals, Inc.)
- Published
- 2014
- Full Text
- View/download PDF
28. Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients.
- Author
-
Adès L, Chevret S, Raffoux E, Guerci-Bresler A, Pigneux A, Vey N, Lamy T, Huguet F, Vekhoff A, Lambert JF, Lioure B, de Botton S, Deconinck E, Ferrant A, Thomas X, Quesnel B, Cassinat B, Chomienne C, Dombret H, Degos L, and Fenaux P
- Subjects
- Cytarabine administration & dosage, Daunorubicin administration & dosage, Early Termination of Clinical Trials, Female, Follow-Up Studies, Humans, Leukemia, Promyelocytic, Acute pathology, Male, Middle Aged, Recurrence, Risk Factors, Treatment Outcome, Tretinoin administration & dosage, Antineoplastic Combined Chemotherapy Protocols, Leukemia, Promyelocytic, Acute drug therapy
- Abstract
All-trans retinoic acid (ATRA) combined to anthracycline-based chemotherapy is the reference treatment of acute promyelocytic leukemia (APL). Whereas, in high-risk patients, cytarabine (AraC) is often considered useful in combination with anthracycline to prevent relapse, its usefulness in standard-risk APL is uncertain. In APL 2000 trial, patients with standard-risk APL [i.e., with baseline white blood cell (WBC) count <10,000/mm(3) ] were randomized between treatment with ATRA with Daunorubicin (DNR) and AraC (AraC group) and ATRA with DNR but without AraC (no AraC group). All patients subsequently received combined maintenance treatment. The trial had been prematurely terminated due to significantly more relapses in the no AraC group (J Clin Oncol, (24) 2006, 5703-10), but follow-up was still relatively short. With long-term follow-up (median 103 months), the 7-year cumulative incidence of relapses was 28.6% in the no AraC group, compared to 12.9% in the AraC group (P = 0.0065). In standard-risk APL, at least when the anthracycline used is DNR, avoiding AraC may lead to an increased risk of relapse suggesting that the need for AraC is regimen-dependent., (Copyright © 2013 Wiley Periodicals, Inc.)
- Published
- 2013
- Full Text
- View/download PDF
29. Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial.
- Author
-
Knauf WU, Lissitchkov T, Aldaoud A, Liberati AM, Loscertales J, Herbrecht R, Juliusson G, Postner G, Gercheva L, Goranov S, Becker M, Fricke HJ, Huguet F, Del Giudice I, Klein P, Merkle K, and Montillo M
- Subjects
- Antineoplastic Agents, Alkylating adverse effects, Bendamustine Hydrochloride, Chlorambucil adverse effects, Disease-Free Survival, Female, Humans, Male, Middle Aged, Nitrogen Mustard Compounds adverse effects, Antineoplastic Agents, Alkylating therapeutic use, Chlorambucil therapeutic use, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Nitrogen Mustard Compounds therapeutic use
- Abstract
The efficacy of bendamustine versus chlorambucil in a phase III trial of previously untreated patients with Binet stage B/C chronic lymphocytic leukaemia (CLL) was re-evaluated after a median observation time of 54 months in May 2010. Overall survival (OS) was analysed for the first time. At follow-up, investigator-assessed complete response (CR) rate (21·0% vs 10·8%), median progression-free survival (21·2 vs 8·8 months; P < 0·0001; hazard ratio 2·83) and time to next treatment (31·7 vs 10·1 months; P < 0·0001) were improved for bendamustine over chlorambucil. OS was not different between groups for all patients or those ≤65 years, >65 years, responders and non-responders. However, patients with objective response or a CR experienced a significantly longer OS than non-responders or those without a CR. Significantly more patients on chlorambucil progressed to second/further lines of treatment compared with those on bendamustine (78·3% vs 63·6%; P = 0·004). The benefits of bendamustine over chlorambucil were achieved without reducing quality of life. In conclusion, bendamustine is significantly more effective than chlorambucil in previously untreated CLL patients, with the achievement of a CR or objective response appearing to prolong OS. Bendamustine should be considered as a preferred first-line option over chlorambucil for CLL patients ineligible for fludarabine, cyclophosphamide and rituximab., (© 2012 Blackwell Publishing Ltd.)
- Published
- 2012
- Full Text
- View/download PDF
30. l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial.
- Author
-
Domenech C, Thomas X, Chabaud S, Baruchel A, Gueyffier F, Mazingue F, Auvrignon A, Corm S, Dombret H, Chevallier P, Galambrun C, Huguet F, Legrand F, Mechinaud F, Vey N, Philip I, Liens D, Godfrin Y, Rigal D, and Bertrand Y
- Subjects
- Adolescent, Adult, Antineoplastic Agents adverse effects, Antineoplastic Agents blood, Antineoplastic Agents therapeutic use, Asparaginase adverse effects, Asparaginase blood, Asparaginase therapeutic use, Bioreactors, Child, Child, Preschool, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Delivery Systems, Humans, Infant, Male, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma blood, Young Adult, Antineoplastic Agents administration & dosage, Asparaginase administration & dosage, Drug Carriers, Erythrocytes enzymology, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy
- Abstract
l-asparaginase encapsulated within erythrocytes (GRASPA(®) ) should allow serum asparagine depletion over a longer period than the native form of the enzyme, using lower doses and allowing better tolerance. The GRASPALL 2005-01 study, a multicentre randomized controlled trial, investigated three doses of GRASPA(®) for the duration of asparagine depletion in a phase I/II study in adults and children with acute lymphoblastic leukaemia (ALL) in first relapse. Between February 2006 and April 2008, 18 patients received GRASPA(®) (50 iu/kg: n = 6,100 iu/kg: n = 6, 150 iu/kg: n = 6) after randomization, and six patients were assigned to the Escherichia coli native l-asparaginase (E. colil-ASNase) control group. GRASPA(®) was effective at depleting l-asparagine. One single injection of 150 iu/kg of GRASPA(®) provided similar results to 8 × 10,000 iu/m(2) intravenous injections of E. colil-ASNase. The safety profile of GRASPA(®) showed a reduction in the number and severity of allergic reactions and a trend towards less coagulation disorders. Other expected adverse events were comparable to those observed with E. colil-ASNase and there was also no difference between the three doses of GRASPA(®) ., (© 2011 Blackwell Publishing Ltd.)
- Published
- 2011
- Full Text
- View/download PDF
31. One versus two high-dose cytarabine-based consolidation before autologous stem cell transplantation for young acute myeloblastic leukaemia patients in first complete remission.
- Author
-
Jourdan E, Rigal-Huguet F, Marit G, Vey N, Dastugue N, Fegueux N, Molina L, Gastaut JA, Legros L, Zerazhi H, Cailleres S, Bauduer F, Bordessoule D, Attal M, Blaise D, and Pigneux A
- Subjects
- Adolescent, Adult, Daunorubicin administration & dosage, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Multivariate Analysis, Recurrence, Remission Induction, Risk Factors, Survival Analysis, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cytarabine administration & dosage, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute drug therapy
- Abstract
We report on a randomized trial aimed to determine the impact of a second consolidative high-dose cytarabine-based chemotherapy (HiDAC) in patients with acute myeloid leukaemia prior to an autologous stem cell transplantation (ASCT). Patients aged 18-60 years, in complete remission (CR) received a first consolidation with daunorubicin and cytarabine at reduced dose. Patients not allocated to allogeneic transplantation received one course of HiDAC and then were randomized to receive an ASCT immediately (HiDAC 1 group) or after one more course of HiDAC (HiDAC 2 group). Out of the 437 initial patients, 351 achieved CR (80%), of those 277 (79%) were eligible for first HiDAC, and 128 (36%) were randomized (HiDAC 1:65, HiDAC 2:63). Overall survival, leukaemia-free survival and cumulative incidence of relapse and non-relapse deaths were 41% and 53% (P = 0.14), 39% and 48% (P = 0.12), 57% and 47% (P = 0.11), 8% and 8% (P = 0.95) for HiDAC 1 and HiDAC 2 groups, respectively. Further studies are warranted with a larger number of patients to test the place of a second course of HiDAC in this setting.
- Published
- 2005
- Full Text
- View/download PDF
32. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial.
- Author
-
De Botton S, Chevret S, Sanz M, Dombret H, Thomas X, Guerci A, Fey M, Rayon C, Huguet F, Sotto JJ, Gardin C, Cony Makhoul P, Travade P, Solary E, Fegueux N, Bordessoule D, San Miguel J, Link H, Desablens B, Stamatoullas A, Deconinck E, Geiser K, Hess U, Maloisel F, Castaigne S, Preudhomme C, Chomienne C, Degos L, and Fenaux P
- Subjects
- Adult, Anthracyclines administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Chromosomes, Human, Pair 12, Chromosomes, Human, Pair 16, Chromosomes, Human, Pair 21, Chromosomes, Human, Pair 6, Chromosomes, Human, Pair 7, Chromosomes, Human, Pair 9, Cohort Studies, Cytarabine administration & dosage, Daunorubicin administration & dosage, Disease-Free Survival, Female, Humans, Leukemia, Promyelocytic, Acute drug therapy, Leukemia, Promyelocytic, Acute mortality, Male, Middle Aged, Prognosis, Remission Induction, Survival Rate, Translocation, Genetic, Tretinoin therapeutic use, Trisomy, Chromosome Aberrations, Chromosomes, Human, Pair 15, Chromosomes, Human, Pair 17, Chromosomes, Human, Pair 8, Leukemia, Promyelocytic, Acute genetics
- Abstract
In spite of the recent improvement in the outcome of acute promyelocytic leukaemia (APL) with treatment combining all trans retinoic acid (ATRA) and chemotherapy (CT), some patients with this disease still have a poor outcome. The prognostic significance of chromosomal abnormalities in addition to t(15;17) in APL is uncertain. We examined the prognostic significance of secondary chromosomal changes in 292 patients included in a European trial who were treated with ATRA and CT. The incidence of chromosomal abnormalities in addition to t(15;17) was 26% and trisomy 8 was the most frequent secondary change (46% of the cases with secondary changes). No significant differences were seen with regard to age, sex, initial white blood cell count, % of circulating blasts, platelet count, fibrinogen level and incidence of microgranular variants between patients with or without additional rearrangements. Outcome was also similar between patients with t(15;17) alone and patients with t(15;17) and other clonal abnormalities for complete remission (92% vs. 93% respectively), event-free survival at 2 years (76.1% vs. 78.1% respectively), relapse at 2 years (16.7% vs. 11.6% respectively) and overall survival at 2 years (79.9% vs. 79.5% respectively). Analysis according to the type of induction treatment (ATRA followed by CT or ATRA plus CT) or the type of maintenance treatment (with ATRA, low-dose CT or both) also failed to show any difference between the two groups. Thus, in a large cohort of APL patients treated with ATRA and CT, additional chromosomal abnormalities had no impact on prognosis.
- Published
- 2000
- Full Text
- View/download PDF
33. Hemolytic-uremic syndrome in a patient with chronic myelogenous leukemia treated with interferon alpha.
- Author
-
Schlaifer D, Dumazer P, Spenatto N, Mignon-Conte M, Brousset P, Lumbroso C, Cooper M, Muller C, Huguet F, and Attal M
- Subjects
- Adult, Humans, Male, Hemolytic-Uremic Syndrome etiology, Interferon-alpha adverse effects, Interferon-alpha therapeutic use, Leukemia, Myelogenous, Chronic, BCR-ABL Positive complications, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy
- Published
- 1994
- Full Text
- View/download PDF
34. Epstein-Barr virus in familial Hodgkin's disease.
- Author
-
Schlaifer D, Rigal-Huguet F, Robert A, Attal M, Abbal M, Fonck Y, Laurent G, Pris J, Delsol G, and Brousset P
- Subjects
- Female, Herpesvirus 4, Human genetics, Hodgkin Disease genetics, Humans, In Situ Hybridization, Male, Pedigree, RNA, Viral analysis, Herpesvirus 4, Human isolation & purification, Hodgkin Disease virology
- Abstract
Hodgkin's disease (HD) has been found to be linked to Epstein-Barr virus (EBV). Familial HD (FHD) may be related to a possible unknown agent. We have determined whether EBV small RNAs (EBERs) were found in Reed-Sternberg cells from FHD. Five families were studied for histological subtype and EBER presence. There was a striking similarity in FHD subtypes of each family and 3/11 (27%) of the cases were EBER positive. In conclusion, EBV EBERs are only infrequently found in FHD and other factors including viruses different from EBV should be further investigated in FHD.
- Published
- 1994
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.